The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | DS3790: phase I/II evaluation of a novel CD37-directed ADC in non-Hodgkin lymphoma
Gilles Salles, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a first-in-human Phase I/II study (NCT07220616) evaluating DS3790, a CD37-directed DXd antibody-drug conjugate (ADC), in non-Hodgkin lymphoma. Prof. Salles highlights the potential of this novel therapy, which combines CD37 targeting with a topoisomerase I inhibitor payload. The trial is currently ongoing, aiming to assess the tolerability and efficacy of DS3790. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This first-in-human study is the first study assessing the role of a CD37 dedicated ADC, antibody drug conjugate, which is linked with DXd, which is a topoisomerase inhibitor. This toxin is very well known in the field of solid tumors, which is developed in breast cancer and approved in breast cancer, in lung cancer, and it’s the first time this toxin is brought into the field of heme malignancies...
This first-in-human study is the first study assessing the role of a CD37 dedicated ADC, antibody drug conjugate, which is linked with DXd, which is a topoisomerase inhibitor. This toxin is very well known in the field of solid tumors, which is developed in breast cancer and approved in breast cancer, in lung cancer, and it’s the first time this toxin is brought into the field of heme malignancies. What is really interesting is that CD37 antibodies have shown to be in the past efficient, but this is really the first ADC targeting this pathway and having these topoisomerase inhibitors delivered into the cell. We are at the beginning of the study. The first cohort was accrued and re-enrolled. The second cohort, we are looking for efficacy and, of course, tolerability. But it’s interesting, it’s a new target, it’s a new toxin, so it could be something very promising for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
